MS4A1 and B-cell chronic lymphocytic leukemia: Additionally, a phase I/II clinical trial has demonstrated the potential of phosphatidylinositol-3-kinase (PI3K) inhibitors, such as umbralisib, and the anti-CD20 antibody ublituximab, particularly for CLL patients who are refractory to ibrutinib [121].